he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查询信源地址
- 2022-05-04专家共识:儿童遗传病遗传侦测临床应用
- 2022-05-02癫痫孕妇使用抗癫痫药物会增加流产可能性吗?
- 2022-04-282013年国际抗癫痫青年组织抗癫痫药使用指南
- 2022-04-25全面性癫痫的先兆研究成果
- 2022-04-20癫痫孕妇适用抗癫痫药物会增加流产风险吗?
- 2021-12-27手术治疗癫痫病费用约是多少钱
- 癫痫孕妇适用抗癫痫药物会增加流产风险吗?
- 手术治疗癫痫病费用约是多少钱
- 病卒中后癫痫首选用药有哪些?解答病卒中后癫痫的4大问题
- 癫痫孕妇适用抗癫痫药物会增加流产风险吗?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 综述:癫痫持续状态诊治最新进展
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫定位新方法:无框架立体定向脑电图技术
- 2016AAN:神经专家发表了有前途的专业见解
- 病例学习:伴皮层下囊肿的巨脑性脑白质病
- 北京癫痫手术费用
- 癫痫猝死:凶手是谁?
- 2013国际抗癫痫联合会抗癫痫药用指南
- 抗癫痫药物预防新发癫痫:任重而道远
- 什么是治疗癫痫 癫痫有这些偏方?
- 治疗癫痫的最低费用
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 心率多少正常 如何保持正常心率不变
- 月经期间要注意 有些药物和食物不能食用
- 北京癫痫医院治疗费用
- 上海率先探索异地就医门诊费直接结算
- 月经性癫痫患者妊娠期癫痫控制更好
- Medpage Today:不同类型的抗癫痫药物更有利
- 黑芝麻的营养价值 吃黑芝麻的好处
- 泡温泉时不能忽视的事情
- 中医如何治疗癫痫 癫痫预防?
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 癫痫治疗障碍仍难以克服
- 三庚酸酯可治疗1型转运体缺陷综合征
- UCB的Vimpat癫痫新适应症在美国获批
- 癫痫患者手术评估新型工具
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 药企科学实验(研发/QC)规范管理与 ICH指南及药典最新进展
- 癫痫病该怎么做好防治呢
- 难治性癫痫病怎么进行疗程
- [力荐收藏]癫痫急救要点及常见误区~!
- 20130712养生:杨红宣讲癫痫病人不用吃什么
- 骨骼肌胶质瘤释放的谷氨酸盐可诱发癫痫
- 首次痫性发作该如何处理?这 3 个问题须理清
- 手术化疗局灶耐药性癫痫效果佳
- 经典病例解析:手把手教徒你治疗强攻击性患者
- 癫痫病的少用症状是什么样
- 难治性癫痫“难”在哪里?病人如何少走弯路!
- 20120816cctv10健康之路:周文静揭秘神经系统结构
- 癫痫的患者是什么
- 二次取栓安全性吗?看看这个研究研究结果